AI imaging interpreter gains FDA’s OK for prostate care
The FDA has cleared an AI tool that helps radiologists diagnose or rule out prostate cancer on MRI scans.
Valencia, Spain-based Quibim says its qp-Prostate product extracts quantitative imaging data in key regions of and around the gland, which can cut a radiologist’s reading time while augmenting his or her visual inspection.
The company suggests such augmentation can facilitate early detection and avoid invasive biopsies and unnecessary surgeries.
Quibim notes prostate cancer hits 1.4 million men each year and is the second most common cancer in men, behind only skin cancer.
Announcement here.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.